JPY 610.0
(-0.65%)
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2023 | 982.41 Million JPY | 25.26% |
2022 | 784.3 Million JPY | 45.26% |
2021 | 539.94 Million JPY | 13.47% |
2020 | 475.84 Million JPY | -48.22% |
2019 | 919 Million JPY | 0.0% |
Year | Operating Expenses | Operating Expenses Growth |
---|---|---|
2024 Q1 | 241 Million JPY | 5.89% |
2023 Q2 | 232.15 Million JPY | -9.95% |
2023 Q1 | 257.81 Million JPY | 6.39% |
2023 Q4 | 227.58 Million JPY | -14.07% |
2023 Q3 | 264.85 Million JPY | 14.09% |
2023 FY | 982.41 Million JPY | 25.26% |
2022 Q3 | 219 Million JPY | 28.34% |
2022 FY | 784.3 Million JPY | 45.26% |
2022 Q4 | 242.32 Million JPY | 10.65% |
2022 Q2 | 170.64 Million JPY | 0.0% |
2021 FY | 539.94 Million JPY | 13.47% |
2020 FY | 475.84 Million JPY | -48.22% |
2019 FY | 919 Million JPY | 0.0% |
Name | Operating Expenses | Operating Expenses Difference |
---|---|---|
Kyowa Kirin Co., Ltd. | 224.77 Billion JPY | 99.563% |
Astellas Pharma Inc. | 1034.29 Billion JPY | 99.905% |
Chugai Pharmaceutical Co., Ltd. | 258.88 Billion JPY | 99.621% |
Ono Pharmaceutical Co., Ltd. | 212.44 Billion JPY | 99.538% |
Santen Pharmaceutical Co., Ltd. | 111.97 Billion JPY | 99.123% |
JCR Pharmaceuticals Co., Ltd. | 23.72 Billion JPY | 95.858% |
Daiichi Sankyo Company, Limited | 974.77 Billion JPY | 99.899% |
Otsuka Holdings Co., Ltd. | 1115.15 Billion JPY | 99.912% |